Oct 30 (Reuters) - Medical device maker Dexcom ( DXCM )

topped Wall Street estimates for third-quarter results on

Thursday, driven by robust demand for its continuous glucose

monitoring systems.

Interim CEO Jake Leach said the company's performance was

driven by continued expansion of access to the G7 system, which

helps people with diabetes track their glucose levels without

finger pricks.

During the quarter, Dexcom ( DXCM ) added coverage for G7 under

Canada's Ontario Drug Benefit Program, making it available to

more people on insulin therapy.

The company also launched an AI-powered meal logging feature

in both its G7 and Stelo apps, aimed at helping users better

understand how food affects their glucose levels.

Stelo, Dexcom's ( DXCM ) over-the-counter CGM for adults not on

insulin, brought in over $100 million in revenue in its first

year. The device marks Dexcom's ( DXCM ) push into a broader consumer

health market, targeting people with Type 2 diabetes or those

looking to monitor glucose for wellness.

Growing awareness around diabetes care, wider insurance

coverage and a shift toward non-invasive monitoring have helped

fuel demand for CGMs like Dexcom's ( DXCM ).

Dexcom ( DXCM ) now expects full-year revenue between $4.63 billion

and $4.65 billion, slightly higher than its prior view of $4.60

billion to $4.63 billion. Analysts expectations were at $4.63

billion.

On an adjusted basis, the company earned a profit of 61

cents per share in the quarter ended September 30, beating the

analysts' average estimate of 57 cents per share, according to

data compiled by LSEG.

Dexcom ( DXCM ) reported third-quarter revenue of $1.21 billion,

beating analysts' estimates of $1.18 billion.

Dexcom ( DXCM ) also submitted a new insulin dosing tool, Smart

Basal, to the U.S. FDA for review, it said.